2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Vaccines, Bispecific Antibody Therapy, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Practice Models, Diseases, Bleeding and Clotting, Thromboembolism, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Measurable Residual Disease, ALL, B Cell Lymphoma, T Cell Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

5044 Clinical characteristics and outcomes of adults with PAX5-altered B-cell acute lymphoblastic leukemia

Dany Nassar, MD, Elias Jabbour, MD2, Nicholas Short, MD3, Nitin Jain, MD4, Farhad Ravandi, MD5, Tapan Kadia I, MD6, Naval Daver, MD7, Alex Bataller, MD, PhD8, Alexandre Bazinet, MD, MSc9, Jayastu Senapati, MBBS, MD, DM10, Musa Yilmaz, MD11, Fadi G. Haddad, MD12, Rebecca Garris13, Guillermo Garcia-Manero, MD14, Hagop Kantarjian, MD15, Hannah Goulart, MD16
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
10 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
11 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
12 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
13 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
14 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
15 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
16 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Introduction:

PAX5 is among the most frequently altered transcription factor genes in B-cell acute lymphoblastic leukemia (ALL); however, specific alteration subtypes and their influence on the prognosis of adults treated with contemporary immunotherapy-based treatment regimens remains poorly defined. We evaluated the clinical characteristics, genomic features, treatment outcomes and prognostic significance of PAX5 alterations in adults with newly diagnosed B-ALL.

Methods:

We retrospectively analyzed adults with newly diagnosed PAX5-altered B-ALL treated at our institution from 2017-2026. Alterations were identified by optical genome mapping (OGM), targeted next generation sequencing (NGS), single-nucleotide polymorphism array, and/or RNA sequencing. We evaluated baseline characteristics, measurable residual disease (MRD) responses, overall survival (OS), and event-free survival (EFS).

Results:

Adults with newly diagnosed B-ALL who underwent at least one assessment for a PAX5 alteration by either NGS (n = 385), OGM (n = 137), and/or SNP microarray testing (n = 124) were evaluated. Eighty-eight patients had with PAX5-altered B-ALL. The median age was 50 years (range, 18–85), 31 patients (36%) were >60 years, and 45 (51%) were male. Forty-four patients (50%) had Philadelphia chromosome–positive (Ph+) ALL, 44 (50%) patients had Ph-negative (Ph−) ALL, of which 12 patients (13%) had Ph-like ALL.

PAX5 alterations included isolated deletions in 54 patients (61%), isolated mutations in 21 (23%), amplification in 1 (1%), fusions in 3 (3%), concurrent deletion and mutation in 4 (5%), and concurrent fusion and deletion in 5 (6%) including 1 with a mutation. The most frequent recurrent PAX5 mutation was P80R, identified in 8 patients (n=23, 38%) with the remaining patients (n=15) harboring frameshift, nonsense, stop-loss, splice-site or other missense variants. Among PAX5-altered ALL, patients were Ph+ ALL were more likely to have deletions (42/44 [95%]), whereas patients with Ph-ALL were more likely to have mutations (24/44 [52%]). Among PAX5-altered Ph-negative B-ALL, cytogenetics included diploid in 12 (14%), complex cytogenetics (≥5 abnormalities) in 4 (5%), low hypodiploidy/near-triploidy in 2 (2%), insufficient metaphases/miscellaneous in 26 (29%). IKZF1 alterations were present in 22 patients (25%), whereas JAK/STAT pathway alterations were present in 12 (13%) patients.

60 patients (68%) received frontline blinatumomab (blina)-containing therapy, 20 (23%) were Ph+ and 40 (45%) Ph−ALL; 30 pts (34%), all with Ph− ALL, also received inotuzumab. In the Ph+ cohort, 43/44 patients (98%) achieved complete remission (CR), 31/39 (79%) achieved multiparameter flow cytometry (FCM) MRD negativity, 12/20 (60%) achieved complete molecular response, and 4/8 (50%) achieved NGS IG/TR MRD negativity. FCM MRD negativity was more frequent with blina-containing therapy vs no blina (90% vs 54%; P=0.01). In the Ph− cohort, all 44 patients achieved CR, 34 of 42 evaluable patients (81%) achieved FCM MRD negativity; FCM MRD negativity occurred in 33 of 40 patients (83%) treated with blina and 1 of 2 (50%) treated without blina (P=0.35). A total of 8/18 evaluable patients (44%) achieved NGS IG/TR MRD negativity.

After a median follow-up of 42 months (range, 0.2–179), 4-year EFS rate was 59% for Ph+ ALL and 64% for Ph− ALL (P=0.91), and 4-year OS rates were 68% and 76%, respectively (P=0.61). When stratified by Ph status and blina exposure, OS differed across the four groups (P=0.0069), with the highest 5-year OS rate in blina-treated Ph+ and Ph− patients (91% and 80%, respectively); among Ph+ patients specifically, blina was associated with improved OS (HR, 0.21; P=0.0072), with median OS not reached versus 67 months without blina; among Ph- patients specifically, median OS was not reached with blina versus 16.9 months without blina; the difference was not statistically significant likely due to the small no blina subgroup (n=4). IKZF1 alterations and were not significantly associated with OS (P=0.17). JAK/STAT pathway alterations were also not associated with OS (P=0.63).

Conclusion:

Distinct patterns of PAX5 alterations were observed across our cohort of adults with Ph+ and Ph− B-ALL. With the incorporation of blinatumomab, high FCM MRD-negativity rates were achieved, translating to favorable survival outcomes. Further evaluation is needed to assess the impact of PAX5 alterations with the availability of more sensitive methods of MRD assessment. 

Dany Nassar, MD: No relevant conflicts of interest to declare.